Clinical trials for Acute promyelocytic leukemia
37 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital · PI: Shujiao He, Dr
- RECRUITINGPhase 3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPhase 3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGN/ANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University · PI: Zhangbiao Long
- RECRUITINGPhase 3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONN/ANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University · PI: ZhangBiao Long, Doctor
- RECRUITINGPhase 1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD · PI: Richard Stone, MD
- RECRUITINGPhase 3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo · PI: Global Clinical Leader
- RECRUITINGPhase 2NCT07514936Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid LeukaemiaChinese PLA General Hospital · PI: Dahong Liu, Doctor
- RECRUITINGPhase 2NCT05554406Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)National Cancer Institute (NCI) · PI: Paul J Shami
- RECRUITINGNCT06439199Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive ChemotherapyNantes University Hospital
- RECRUITINGPhase 2NCT06451861Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AMLGuangdong Provincial People's Hospital · PI: Jianyu Weng
- RECRUITINGPhase 3NCT06389292A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaAscentage Pharma Group Inc. · PI: Jianxiang Wang, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT06928376A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML PatientsChinese PLA General Hospital
- RECRUITINGPhase 2NCT06982274Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic LeukemiaInstituto do Cancer do Estado de São Paulo · PI: Eduardo M Rego, MD PhD
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT06544109Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPhase 3NCT05586074HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLSunshine Lake Pharma Co., Ltd. · PI: Jie Jin, MD, PhD
- RECRUITINGPHASE2, PHASE3NCT05805098Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLThe First Affiliated Hospital of Soochow University · PI: Huiying Qiu, PhD
- RECRUITINGN/ANCT05832320Optimum Induction Therapy of Low-risk APLPeking University People's Hospital · PI: Xiaolu Zhu, Doctor
- RECRUITINGPhase 3NCT05183035Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)PedAL BCU, LLC · PI: Seth Karol, MD
- RECRUITINGPhase 4NCT07561892Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).Fujian Medical University Union Hospital · PI: Yuanzhong Chen, MD
- RECRUITINGNCT04897490RWE of 1st Line Treatment With ATO/ATRA for Adult APLGrupo Argentino de Tratamiento de la Leucemia Aguda · PI: María José Mela Osorio, Dr.
- RECRUITINGPhase 2NCT04687176Frontline Oral Arsenic Trioxide for APLThe University of Hong Kong · PI: Harry Gill, MD
- RECRUITINGPhase 3NCT04168502Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPhase 3NCT04293562A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsChildren's Oncology Group · PI: Todd M Cooper
- RECRUITINGPhase 1NCT02390635PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid LeukemiaM.D. Anderson Cancer Center · PI: Dawid Schellingerhout
- ACTIVE NOT RECRUITINGPhase 3NCT04027309A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland · PI: M. Raaijmakers, Prof. Dr.
- RECRUITINGPhase 2NCT04793919Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaAssociazione Italiana Ematologia Oncologia Pediatrica · PI: Fanco Locatelli, Prof
- ACTIVE NOT RECRUITINGPhase 3NCT03839771A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland · PI: B.J. Wouters
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03793478Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodDaiichi Sankyo · PI: Global Clinical Leader
- ACTIVE NOT RECRUITINGN/ANCT03253848Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic LeukemiaECOG-ACRIN Cancer Research Group · PI: Anand Jillella
- ACTIVE NOT RECRUITINGPhase 3NCT02665065Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaActinium Pharmaceuticals · PI: Avinash Desai, MD
- ACTIVE NOT RECRUITINGNCT02938858French Registry of First-line Treatment of Acute Promyelocytic LeukemiaGroupe Francophone des Myelodysplasies · PI: Pierre FENAUX, MD
- ACTIVE NOT RECRUITINGPhase 3NCT02339740Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic LeukemiaChildren's Oncology Group · PI: Matthew A Kutny
- ACTIVE NOT RECRUITINGPhase 2NCT01985061Evaluation of 3 Different Doses of IV BusulfanInstitut Paoli-Calmettes · PI: Didier BLAISE, MD PhD
- RECRUITINGPhase 2NCT01409161Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaM.D. Anderson Cancer Center · PI: Farhad Ravandi-Kashani
- ACTIVE NOT RECRUITINGNCT00003861Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic LeukemiaAlliance for Clinical Trials in Oncology · PI: Wendy Stock, MD